Drug intelligence / Profile preview

DN-105

Development stage: Preclinical
Lead developer: DAAN Bio Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DN-105 is a next-generation biparatopic monoclonal antibody targeting Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5), developed by DAAN Bio Therapeutics. The antibody is engineered for enhanced internalization, making it a specialized platform for conjugation with proprietary linker-payloads to form antibody-drug conjugates (ADCs). By binding to two distinct epitopes on CEACAM5, DN-105 aims to improve target engagement and cellular uptake compared to traditional monoparatopic antibodies. It is currently in preclinical development, with an Investigational New Drug (IND) submission targeted for approximately the first quarter of 2028.

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)

Beyond the preview

Go deeper on DN-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DN-105.

Explore the full profile